Can we target p53 therapeutically?
The Francis Crick Institute in London has an admirable program of engagement with the public and external researchers.
Attending a Crick Lecture recently presented by Cancer Research UK (CRUK) Chief Scientific Officer, Prof Karen Vousden CBE FRS, reminded me of my days as a PhD student at nearby King’s College London.
Regular BSB readers will recall that Prof Charles Swanton FRS is the Chief Clinician of CRUK.
In her Crick lecture, Prof Vousden elegantly explained to the audience why p53 mattered and how it might be targeted by small molecules.
What is the potential of this research for translational drug development? In this post, we take a look at new developments in the basic understanding of what p53 does, the current state of targeting p53 and Prof Vousden’s latest approaches.
To learn more from our latest biotech and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
